Bicara Therapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Bicara Therapeutics Inc's ROI in the second quarter of 2026?
Bicara Therapeutics Inc recorded a cumulative net loss of $-185 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -41.45%.

Within the Healthcare sector 251 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3487 to 3549.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	-5.71 %	4.6 %	39.4 %	145.95 %	768.17 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	469	514	402	404	436
Return On Investment (TTM)	-41.45 %	-35.83 %	-32.44 %	-27.14 %	-21.65 %
BCAX's Overall Ranking	# 3549	# 3487	# 3149	# 3145	# 2606
Seq. Investment Change TTM	1.85 %	3.25 %	-5.02 %	-5.59 %	12.97 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-185	-157	-138	-122	-103

BCAX Company Profile >> Back to BCAX Roi Comparisons >> See Annual BCAX Return On Investment

Return On Investment BCAX's Ranking
Within:	No.
Industry	# 86
Sector	# 252
Overall	# 3549

Return On Investment Statistics
High	Average	Low
-13.72 %	-27.06 %	-41.45 %
(Sep 30 2024)		(Jun 30 2026)

Financial Statements
Bicara Therapeutics Inc's II. Quarter Investments	$ 469 Millions	BCAX's Balance sheet
Bicara Therapeutics Inc's II. Quarter Income	$ -55 Millions	Quarterly BCAX's Income Statement
BCAX's Income by Division		See BCAX's Income by Division

BCAX Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024
Total Investments in Millions	402	492	0	0	0
Y / Y Investment Growth	-18.28 %	-	-	-	-
Net Income in Millions	-138	-68	0	0	0
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-34.31 %	-13.82 %	-	-	-

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
BCAX's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for BCAX's Competitors
Subscribers only: Roi for Bicara Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for BCAX's Customers

Other Ratios
BCAX's Roa	BCAX's Inventory Turnover Ratio	BCAX's Growth Rates	BCAX's Dividend Statistics
	BCAX's Profitability Ratios	BCAX's Asset Turnover Ratio	BCAX's Dividend Growth
BCAX's Roe	BCAX's Valuation Ratios	BCAX's Financial Strength Ratios	BCAX's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector

ROI

Date modified: 2026-09-26T07:43:05+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.